The leading causes of death in the United States (U.S.) are heart disease and strokes.…
Author: Jonathan Block
Jonathan Block is a freelance writer and former MedShadow content editor. He has been an editor and writer for multiple pharmaceutical, health and medical publications, including BioCentury, The Pink Sheet, Modern Healthcare, Health Plan Week and Psychiatry Advisor. He holds a BA from Tufts University and is earning an MPH with a focus on health policy from the CUNY Graduate School of Public Health & Health Policy.
The FDA has approved the first ever treatment for Duchenne muscular dystrophy, going against the recommendation of a panel of independent advisors who months earlier said eteplirsen did not demonstrate clear efficacy in treating the rare muscle-wasting disease. Eteplirsen, which will be marketed under the brand name Exondys 51, won accelerated approval despite the fact that the pivotal clinical trial used by the manufacturer enrolled just 12 boys with Duchenne and did not include a placebo arm. An unusually high number of patient advocates and boys with the disease attended and spoke in favor of the drug’s approval during an…
About MedShadow
MedShadow Foundation is an independent nonprofit health & wellness journalism organization focused on helping to protect lives from the side effects of medication and lower risk with alternative health options.
We help protect your life and the lives of your family by making sure you have the information you need to make informed decisions about the risks, benefits and alternatives to medicines.
Even though MedShadow is nonprofit, we refuse to accept support from pharmaceutical companies or medical device manufacturers. You can be sure that our information is free from the influence of pharmaceutical companies.
FIND ARTICLES
Conditions
Symptoms & Concerns
Medications
SUPPORT
Contribute
Donate
Contact
MedShadow Foundation does not provide medical advice, diagnosis or treatment.
This site complies with the HONcode standard for trustworthy health information.
MedShadow Foundation is a registered 501(c)(3) non-profit organization. MedShadow does not accept advertising or contributions from pharmaceutical companies, medical device manufacturers or political action organizations.
Copyright © 2022, MedShadow Foundation. all rights reserved. Designed by Dante Steward